text
"['\nXII. 상세표\n1. 연결대상 종속회사 현황(상세)\n☞ 본문 위치로 이동\n(단위 : 백만원)\n상호\n설립일\n주소\n주요사업\n최근사업연도말자산총액\n지배관계 근거\n주요종속회사 여부\nHPI, INC.\n2007.08.29\n1 Church St. Suite #103Rockville, MD. 20850 USA\n해외임상시험\n414\n지분율50%초과\nX\n2. 계열회사 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 06월 30일\n)\n(단위 : 사)\n상장여부\n회사수\n기업명\n법인등록번호\n상장\n3\n한올바이오파마(주)\n164111-0000397\n(주)대웅\n131111-0000271\n(주)대웅제약\n134811-0075342\n비상장\n33\n대웅바이오(주)\n134811-0172221\n(주)대웅생명과학\n210111-0013294\n(주)대웅경영개발원\n110111-0776463\n(주)대웅이엔지\n134811-0034421\n(주)대웅개발\n131111-0083649\n(주)아이디에스앤트러스트\n110111-1234006\n㈜에이치알그룹\n110111-2041872\n㈜에스티에이치이솔루션\n110111-4326735\n(주)대웅테라퓨틱스\n135811-0360271\n(주)힐리언스\n110111-3265778\n(주)대웅인베스트먼트\n110111-8587862\n다나아데이터㈜\n110111-6935790\n(주)엠디웰아이엔씨\n110111-3716854\n농업회사법인(주)대웅낙원\n141411-0009986\n(주)아피셀테라퓨틱스\n134511-0431912\n(주)아이엔테라퓨틱스\n134511-0459592\n(주)대웅펫\n110111-7040457\nDaewoong Pharma PHILIPPINES INC.\n-\n북경대웅위업의약과기유한공사\n-\nDaewoong Pharmaceutical(Thailand)Co.,Ltd\n-\nDaewoong America, Inc.\n-\nPT. Daewoong Pharmaceutical(Indonesia)Co.Ltd\n-\n사천대웅생물기술유한공사\n-\nDAEWOONG PHARMACEUTICAL HONGKONG\n-\nDaewoong Pharmaceutical India Pvt.,Ltd\n-\nDaewoong Pharmaceutical Japan Co., Ltd.\n-\nHPI,INC\n-\n요녕대웅제약유한공사\n-\nPT. DAEWOONG INFION\n-\nDaewoong Bio Indonesia\n-\nDaewoong Innovation Holdings\n-\nDaewoong Biologics Indonesia\n-\nPT. SELATOX BIO PHARMA\n-\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 06월 30일\n)\n(단위 : 백만원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nHPI, INC..\n비상장\n2007.09.14\n해외임상시험\n187\n200,200\n100.0\n75\n-\n-\n-\n200,200\n100.0\n75\n993\n671\nImmunoMet Therapeutics, Inc\n비상장\n2015.08.24\n투자\n2,173\n1,285,412\n15.95\n15,541\n-\n-\n-\n1,285,412\n15.95\n15,541\n4,759\n-770\nImmunovant, Inc.\n상장\n2019.01.11\n투자\n5,609\n939,395\n0.81\n21,131\n-\n-\n2,263\n939,395\n0.72\n23,394\n533\n-273\nNurron Pharmaceuticals INC\n비상장\n2021.07.19\n투자\n571\n58,343\n2.37\n571\n-\n-\n-\n58,343\n2.37\n571\n1,463\n-1,083\nAlloplex Biotherapeutics, inc.\n비상장\n2023.01.27\n투자\n827\n-\n-\n577\n9,793\n212\n-\n9,793\n0.27\n789\n7,889\n-2,837\n합 계\n2,483,350\n-\n37,895\n9,793\n212\n2,263\n2,493,143\n-\n40,370\n15,637\n-4,292\n']"
